ABVC BioPharma signs $667M licensing term sheet for CNS drugs with AiBtl BioPharma

ABVC BioPharma has entered a term sheet to license the global rights of its central nervous system drugs, indicated for major depressive disorder and ADHD, to AiBtl BioPharma in a transaction valued at $667 million.

Detected & updated continuously · Source: Nebula